• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

mRECIST for systemic therapies: More evidence is required before recommendations can be made.

作者信息

Edeline Julien, Palmer Daniel, Blanc Jean-Frédéric, Campillo-Gimenez Boris, Merle Philippe, Meyer Tim

机构信息

Medical Oncology, Centre Eugène Marquis, Rennes, France.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, and The Clatterbridge Cancer Centre NHS Foundation Trust, United Kingdom.

出版信息

J Hepatol. 2017 Jul;67(1):195. doi: 10.1016/j.jhep.2017.02.033. Epub 2017 Mar 16.

DOI:10.1016/j.jhep.2017.02.033
PMID:28315710
Abstract
摘要

相似文献

1
mRECIST for systemic therapies: More evidence is required before recommendations can be made.用于全身治疗的改良RECIST标准：在提出建议之前，还需要更多证据。
J Hepatol. 2017 Jul;67(1):195. doi: 10.1016/j.jhep.2017.02.033. Epub 2017 Mar 16.
2
Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.RECIST和mRECIST标准作为中期肝细胞癌患者接受重复碘油化疗栓塞术预后因素的疗效
Acta Radiol. 2015 Dec;56(12):1437-45. doi: 10.1177/0284185114560937. Epub 2014 Dec 5.
3
EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.EASL 和 mRECIST 评价索拉非尼联合经动脉化疗栓塞治疗肝细胞癌的疗效反应可预测患者的生存。
Clin Cancer Res. 2014 Mar 15;20(6):1623-31. doi: 10.1158/1078-0432.CCR-13-1716. Epub 2014 Feb 3.
4
Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.肝移植前经化疗栓塞治疗的肝细胞癌患者，计算机断层扫描显示的肿瘤反应与病理坏死的相关性
Liver Transpl. 2016 Nov;22(11):1491-1500. doi: 10.1002/lt.24615.
5
Reply to: "mRECIST for systemic therapies: More evidence is required before recommendations could be made".回复：“用于全身治疗的改良实体瘤疗效评价标准（mRECIST）：在做出推荐之前需要更多证据”。
J Hepatol. 2017 Jul;67(1):196-197. doi: 10.1016/j.jhep.2017.03.004. Epub 2017 Mar 16.
6
Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.基于强化标准的肝细胞癌经动脉化疗栓塞反应评估的最佳测量方式和方法。
J Vasc Interv Radiol. 2013 Mar;24(3):316-25. doi: 10.1016/j.jvir.2012.10.022. Epub 2013 Jan 9.
7
Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization?在接受经动脉栓塞治疗的肝细胞癌患者中，欧洲肝脏研究学会（EASL）反应和改良实体瘤疗效评价标准（mRECIST）反应对生存有独立影响吗？
J Hepatol. 2012 Jul;57(1):224-5; author reply 225-6. doi: 10.1016/j.jhep.2012.01.016. Epub 2012 Feb 8.
8
Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma.肝细胞癌患者经导管肝动脉化疗栓塞的放射学反应及临床结局
Liver Int. 2014 Feb;34(2):305-12. doi: 10.1111/liv.12270. Epub 2013 Jul 25.
9
Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.使用肿瘤标志物和改良RECIST标准对接受经动脉化疗栓塞术的不可切除肝细胞癌患者的预后进行早期预测
Oncology. 2016;91(6):317-330. doi: 10.1159/000448999. Epub 2016 Oct 27.
10
Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.比较经动脉化疗栓塞治疗肝细胞癌患者肿瘤反应评估方法。
J Hepatol. 2013 Jun;58(6):1181-7. doi: 10.1016/j.jhep.2013.01.039. Epub 2013 Feb 8.

引用本文的文献

1
Radiologic criteria of response to systemic treatments for hepatocellular carcinoma.肝细胞癌全身治疗反应的放射学标准。
Hepat Oncol. 2017 Oct;4(4):129-137. doi: 10.2217/hep-2017-0018. Epub 2017 Nov 17.